Viatris Company Insiders
VTRS Stock | USD 10.17 0.07 0.69% |
Viatris employs about 32 K people. The company is managed by 24 executives with a total tenure of roughly 74667 years, averaging almost 3111.0 years of service per executive, having 1333.33 employees per reported executive. Breaking down Viatris' management performance can provide insight into the firm performance.
Viatris' latest congressional trading
Congressional trading in companies like Viatris, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Viatris by those in governmental positions are based on the same information available to the general public.
2025-05-15 | Senator John Fetterman | Acquired Under $15K | Verify |
Viatris Management Team Effectiveness
The company has return on total asset (ROA) of 0.023 % which means that it generated a profit of $0.023 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1977) %, meaning that it created substantial loss on money invested by shareholders. Viatris' management efficiency ratios could be used to measure how well Viatris manages its routine affairs as well as how well it operates its assets and liabilities.Viatris Workforce Comparison
Viatris is rated second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 123,867. Viatris totals roughly 32,000 in number of employees claiming about 26% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.1 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.1. Viatris Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Viatris insiders, such as employees or executives, is commonly permitted as long as it does not rely on Viatris' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Viatris insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Le Goff Corinne over a month ago Disposition of 7032 shares by Le Goff Corinne of Viatris at 10.2453 subject to Rule 16b-3 | ||
Andrew Enrietti over two months ago Insider Trading | ||
Scott Smith over six months ago Acquisition by Scott Smith of 92503 shares of Viatris subject to Rule 16b-3 | ||
Scott Smith over six months ago Acquisition by Scott Smith of 135828 shares of Viatris subject to Rule 16b-3 | ||
Le Goff Corinne over six months ago Acquisition by Le Goff Corinne of 1173 shares of Viatris subject to Rule 16b-3 | ||
Scott Smith over six months ago Acquisition by Scott Smith of 373555 shares of Viatris subject to Rule 16b-3 | ||
Rajiv Malik over six months ago Disposition of 35816 shares by Rajiv Malik of Viatris at 9.37 subject to Rule 16b-3 | ||
Rajiv Malik over six months ago Disposition of 81761 shares by Rajiv Malik of Viatris subject to Rule 16b-3 |
Viatris Notable Stakeholders
A Viatris stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Viatris often face trade-offs trying to please all of them. Viatris' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Viatris' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Scott Smith | CEO Director | Profile | |
Anthony Mauro | President Markets | Profile | |
Rajiv Malik | President Director | Profile | |
Jeffrey MMS | President Division | Profile | |
Menassie MBA | President Markets | Profile | |
Melissa Trombetta | Head Relations | Profile | |
Andrew Enrietti | Chief Officer | Profile | |
Theodora Mistras | Chief Officer | Profile | |
David Bayles | Chief Officer | Profile | |
Sanjeev Sethi | Chief Officer | Profile | |
Ramkumar Rayapureddy | Chief Officer | Profile | |
Hemanth CFA | Chief Officer | Profile | |
Paul Campbell | Senior Officer | Profile | |
PharmD MBA | Chief Officer | Profile | |
Brian Roman | Global Counsel | Profile | |
Philippe Martin | Chief Officer | Profile | |
Derek Glover | Chief Officer | Profile | |
Robert Coury | Ex Chairman | Profile | |
Lara Ramsburg | Chief Officer | Profile | |
Sanjeev Narula | Chief Officer | Profile | |
Burt Park | Chief Secretary | Profile | |
Peter McCormick | Chief Officer | Profile | |
Jennifer Mauer | Head Brand | Profile | |
Michael Goettler | CEO Director | Profile |
About Viatris Management Performance
The success or failure of an entity such as Viatris often depends on how effective the management is. Viatris management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Viatris management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Viatris management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
The company operates in four segments Developed Markets, Greater China, JANZ, and Emerging Markets. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Viatris operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 37000 people.
Please note, the imprecision that can be found in Viatris' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Viatris. Check Viatris' Beneish M Score to see the likelihood of Viatris' management manipulating its earnings.
Viatris Workforce Analysis
Traditionally, organizations such as Viatris use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Viatris within its industry.Viatris Manpower Efficiency
Return on Viatris Manpower
Revenue Per Employee | 460.6K | |
Revenue Per Executive | 614.1M | |
Net Loss Per Employee | 19.8K | |
Net Loss Per Executive | 26.4M | |
Working Capital Per Employee | 116.9K | |
Working Capital Per Executive | 155.9M |
Additional Tools for Viatris Stock Analysis
When running Viatris' price analysis, check to measure Viatris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viatris is operating at the current time. Most of Viatris' value examination focuses on studying past and present price action to predict the probability of Viatris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viatris' price. Additionally, you may evaluate how the addition of Viatris to your portfolios can decrease your overall portfolio volatility.